The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Stem cell researcher Anna Falk heads Lund University's Center for Advanced Therapies

Portrait of Anna Falk. Photo.
Anna Falk. Photo: Tove Smeds.

Anna Falk, professor at Lund University's Stem Cell Center, will be the director of the newly established Center for Advanced Therapies, LU-ATMP.

"My vision is that we will accelerate the development of all the advanced therapies underway at Lund University. Together with the healthcare and life science industry, we have the potential to make a significant contribution to new breakthrough treatments, and in some cases cures, where there is little to offer today's patients," says Anna Falk.

With many years of experience in stem cell research behind her, Anna Falk will lead the efforts to drive and support ATMP research and development at Lund University's Center for Advanced Therapy Medicinal Products (LU-ATMP). To succeed, stem cell and gene therapy research must be at the forefront. These conditions are in place at Lund University with a large number of research groups conducting internationally successful experimental and translational research in cell, tissue, and gene therapy.

One reason why more and more advanced therapeutic drugs are now being developed is the progress made in molecular biology, genetic engineering, and cell therapy.

"In a report* presented this week, we identified 23 ongoing ATMP projects at the Lund Stem Cell Center alone. There is also other research relevant to ATMP development, both within the Faculty of Medicine and at Lund University," says Anna Falk.

Collaboration with the ATMP center at Skåne University Hospital and the life science industry will also be crucial, highlights Anna Falk.

"ATMPs are not just a trend, advanced therapy medicinal products represent a new era in medicine. Sweden has a vision of becoming a world leader in ATMP development, and there are many ATMP projects with great potential in Swedish academia. It can be likened to unique and valuable seeds that are grown and require very special care to develop into innovative and effective ATMP therapies. I want LU-ATMP to help us harvest them in Sweden," says Anna Falk.

The first step towards a new ATMP treatment is often taken in academia. Even there, says Anna Falk, researchers need support and advice so that the products that go to clinical trials can be scaled up and become a drug or therapy to reach many patients. She will play an important role in this, together with Deputy Center Director Mats Ohlin.

The Lund ATMP Board, group photo.

The LU-ATMP Board

  • Martin L Olsson, professor of transfusion medicine, chief physician, chairman, Faculty of Medicine at Lund University
  • Malin Parmar, professor of cellular neuroscience, representative of the Faculty of Medicine at Lund University
  • Jesper Petersson, head of research Region Skåne, representative for Region Skåne
  • Niels Abel Bonde, CEO of Novo Nordisk, representative of the life science industry
  • Thomas Laurell, professor of biomedical engineering, representative of Lund University of Technology
  • Kristina Eneroth, vice-rector for cooperation and international affairs at Lund University, representative of the university management
  • Student representative (not yet appointed)
Cover of the ATMP Pipeline Report

Advancing Tomorrow's Therapies


Lund University's Center for Advanced Therapeutic Medicines

  • Development of advanced therapy drugs, ATMP, requires working methods that involve both research, healthcare and industry. LU-ATMP has, among other things, as an assignment to develop a so-called pre-GMP center - GMP stands for Good Manufacturing Practice - where researchers working with advanced therapeutic drugs will be supported to more easily take the step from discovery in the research laboratory to practical clinical application.
  • Within the university healthcare in Region Skåne, a number of ATMP treatments are already taking place, both in clinical routine and as part of clinical trials. At Skåne University Hospital, a new clinical ATMP center is being built and this will now be supplemented from June 2023 by LU-ATMP.
  • Center Director Anna Falk, Professor of developmental biology with a focus on neuroscience at Lund University
  • Deputy Center Director Mats Ohlin, Professor of immunotechnology at Lund University of Technology